Live
- 2024 on track to be hottest year on record
- PM Modi’s visit to Solapur: Women applaud ‘Double-Engine’ government’s initiatives
- Nagarkurnool MLA Dr. Kuchukulla Rajesh Reddy Campaigning in Maharashtra Elections
- Wife Kills Husband with Her Lover: Details of Veldanda Murder Case Revealed by SP Gaikwad
- Strict Action on Violations of Food Rights: Telangana Food Commission Chairman Goli Srinivas Reddy
- Smooth Conduct of Group-3 Exams with Strict Security Measures: Collector Badavath Santosh
- Delhi HC orders cancellation of LOC issued against Ashneer Grover, wife
- Shami’s absence a major blow for India in BGT, says Paul Adams
- Will organize protests at borders if attack on minority Hindus in Bangladesh not stopped: Bengal LoP
- Dutch Ambassador Marisa Gerard Meets Telangana CM A. Revanth Reddy in Delhi
Natco Pharma Q4 net falls 23% at 93.2 crore
Natco Pharma reports 14.5% dip in Q1 net
City-based drug firm Natco Pharma on Wednesday reported a 22.59 per cent decline in its consolidated net profit at Rs 93.2 crore for the quarter ended March 31, 2020
Hyderabad: City-based drug firm Natco Pharma on Wednesday reported a 22.59 per cent decline in its consolidated net profit at Rs 93.2 crore for the quarter ended March 31, 2020.
The company had posted a net profit of Rs 120.4 crore for the corresponding period of the previous fiscal. Consolidated total income of the company for the quarter under consideration stood at Rs 477.2 crore. It was Rs 486.7 crore for the same period a year ago.
For the fiscal year ended March this year, the net profit of the company was at Rs 458.1 crore as against Rs 642.4 crore for the previous fiscal year. The company's total income for the financial year ended March 2020 stood at Rs 2,022.4 crore. It was Rs 2,224.7 crore for the year-ago fiscal, it added. "The overall decline in revenue and profits, from the prior year, was primarily due to the continued decline in Hepatitis C product portfolio and to an extent in the oncology segment due to pricing pressures. The company also faced a slowdown in business operations during the fourth quarter due to supply chain issues amid Covid-19 concerns, which were subsequently resolved," Natco Pharma said.
The company's board has recommended a fourth interim dividend of Re 1 per equity share of Rs 2 each, resulting in a total dividend payout of Rs 6.75 per equity share for the year.
